Filana Therapeutics (FLNA) Other Non Operating Income (2021 - 2026)
Filana Therapeutics (FLNA) posted quarterly Other Non Operating Income of $207000.0 for Q2 2026, up 88.18% year-over-year from $110000.0 in Q2 2025, and down 18.18% quarter-over-quarter from $253000.0 in Q1 2026.
Filana Therapeutics (FLNA) Other Non Operating Income (2021 - 2026) Analysis & Trends
Filana Therapeutics' Other Non Operating Income history runs 6 years deep, the most recent figure standing at $207000.0 for Q2 2026.
- In Q2 2026, Other Non Operating Income rose 88.18% year-over-year to $207000.0; the TTM figure through Jun 2026 stood at $747000.0 (down 3.24% YoY), while the FY2025 annual figure was $533000.0, down 57.15% from the prior year.
- Other Non Operating Income for Q2 2026 stood at $207000.0, down from $253000.0 in the prior quarter.
- The five-year high for Other Non Operating Income was $679000.0 in Q4 2022, with the low at $110000.0 in Q2 2025.
- The 5-year median for Other Non Operating Income is $281500.0 (2022), against an average of $353111.1.
- The sharpest annual moves came in 2022 and 2025: Other Non Operating Income jumped 252.27% in 2022, then tumbled 66.5% in 2025.
- Filana Therapeutics' Other Non Operating Income stood at $679000.0 in 2022, then retreated by 13.99% to $584000.0 in 2023, then sank by 59.08% to $239000.0 in 2024, then decreased by 28.45% to $171000.0 in 2025, then grew by 21.05% to $207000.0 in 2026.
- Business Quant data shows FLNA's Other Non Operating Income at $207000.0 in Q2 2026, $253000.0 in Q1 2026, and $171000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 207,000.00 |
| Mar 31, 2026 | 253,000.00 |
| Dec 31, 2025 | 171,000.00 |
| Sep 30, 2025 | 116,000.00 |
| Jun 30, 2025 | 110,000.00 |
| Mar 31, 2025 | 135,000.00 |
| Dec 31, 2024 | 239,000.00 |
| Sep 30, 2024 | 288,000.00 |
| Jun 30, 2024 | 314,000.00 |
| Mar 31, 2024 | 403,000.00 |
| Dec 31, 2023 | 584,000.00 |
| Sep 30, 2023 | 583,000.00 |
| Jun 30, 2023 | 559,000.00 |
| Mar 31, 2023 | 557,000.00 |
| Dec 31, 2022 | 679,000.00 |
| Sep 30, 2022 | 620,000.00 |
| Jun 30, 2022 | 275,000.00 |
| Mar 31, 2022 | 263,000.00 |
| Dec 31, 2021 | 735,000.00 |
| Sep 30, 2021 | 176,000.00 |